Exforge HCT is a combination of three different medications that are used to treat high blood pressure. It contains two different types of drugs, which are an angiotensin II receptor blocker (ARB) and a diuretic. The combination of these two medications helps to lower blood pressure more effectively than either medication alone. Exforge HCT has been approved by the U.S. Food and Drug Administration (FDA) and is available in both generic and brand-name forms. This article will provide a comprehensive guide to the benefits of Exforge HCT and how it can help to manage high blood pressure.
Exforge HCT is a combination of two different medications, amlodipine and valsartan. Amlodipine is a type of calcium channel blocker, which helps to relax blood vessels and reduce the amount of pressure that is put on them. Valsartan is an angiotensin II receptor blocker (ARB), which works to block the action of a hormone called angiotensin II. This hormone can cause the blood vessels to narrow, which can raise blood pressure. The third medication in Exforge HCT is hydrochlorothiazide, which is a diuretic. Diuretics help to reduce the amount of fluid in the body, which can reduce the amount of pressure on the blood vessels.
Exforge HCT works by combining the effects of the three medications. The amlodipine helps to relax the blood vessels, reducing the amount of pressure on them. The valsartan blocks the action of angiotensin II, which helps to keep the blood vessels from narrowing. The hydrochlorothiazide helps to reduce the amount of fluid in the body, which reduces the pressure on the blood vessels. All three medications work together to help lower blood pressure.
Exforge HCT can provide a number of benefits for those with high blood pressure. These benefits include:
Exforge HCT can cause a number of side effects, including:
Exforge HCT is not recommended for those with certain medical conditions, including:
1.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
2.
Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries
3.
Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer
4.
Durvalumab Wins FDA Approval in Limited-Stage SCLC
5.
Early palliative care billing up from 2010 to 2019 for advanced cancer
1.
A Closer Look at the Effects of Sickle Cell on Eyesight
2.
CEUS in Endometrial Cancer: A Tool for Early Myometrial Infiltration Detection
3.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
4.
The Digital Biopsy: How Artificial Intelligence is Redefining Cancer Pathology?
5.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Navigating the Complexities of Ph Negative ALL - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation